Guillain-Barré syndrome

Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy, with about 100 000 people developing the disorder every year worldwide. Under the umbrella term of Guillain-Barré syndrome are several recognisable variants with distinct clinical and pathological features. The se...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 388; no. 10045; pp. 717 - 727
Main Authors: Willison, Hugh J, Jacobs, Bart C, van Doorn, Pieter A
Format: Journal Article
Language:English
Published: England Elsevier Ltd 13.08.2016
Elsevier Limited
Subjects:
Axons - immunology
Axons - pathology
Biomarkers
Campylobacter Infections - complications
Campylobacter Infections - immunology
Campylobacter jejuni
Clinical Trials as Topic
Diagnosis, Differential
Disease Management
Electrophysiology
Epidemiology
Guillain-Barre syndrome
Guillain-Barre Syndrome - complications
Guillain-Barre Syndrome - diagnosis
Guillain-Barre Syndrome - epidemiology
Guillain-Barre Syndrome - immunology
Guillain-Barre Syndrome - physiopathology
Guillain-Barre Syndrome - therapy
Humans
Immunoglobulins, Intravenous - therapeutic use
Infections
Influenza Vaccines - administration & dosage
Influenza Vaccines - adverse effects
Internal Medicine
Medical prognosis
Muscle Weakness - complications
Muscle Weakness - etiology
Neural Conduction - immunology
Neuropathology
Paralysis - complications
Paralysis - immunology
Plasma Exchange
Plasmapheresis
Prognosis
Respiratory Insufficiency - etiology
Respiratory Insufficiency - prevention & control
Treatment Outcome
Vaccines
ISSN:0140-6736, 1474-547X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy, with about 100 000 people developing the disorder every year worldwide. Under the umbrella term of Guillain-Barré syndrome are several recognisable variants with distinct clinical and pathological features. The severe, generalised manifestation of Guillain-Barré syndrome with respiratory failure affects 20–30% of cases. Treatment with intravenous immunoglobulin or plasma exchange is the optimal management approach, alongside supportive care. Understanding of the infectious triggers and immunological and pathological mechanisms has advanced substantially in the past 10 years, and is guiding clinical trials investigating new treatments. Investigators of large, worldwide, collaborative studies of the spectrum of Guillain-Barré syndrome are accruing data for clinical and biological databases to inform the development of outcome predictors and disease biomarkers. Such studies are transforming the clinical and scientific landscape of acute autoimmune neuropathies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(16)00339-1